本文選題：瑞舒伐他汀鈣 + 冠心病�。� 參考：《中國老年學(xué)雜志》2016年08期

【摘要】：目的探討不同劑量瑞舒伐他汀鈣對(duì)老年冠心病(CHD)伴高脂血癥患者血脂、血清超敏C反應(yīng)蛋白(hs-CRP)以及頸動(dòng)脈內(nèi)膜中層厚度(IMT)的影響。方法選擇2011年1月至2015年3月因CHD伴高脂血癥入院接受治療的270例老年患者,隨機(jī)均衡分為三組各90例,均采用降血糖、降血壓、硝酸酯類藥物及抗凝等常規(guī)治療方式,對(duì)照組口服瑞舒伐他汀鈣,5 mg/次,1次/d,觀察1組在對(duì)照組基礎(chǔ)上將瑞舒伐他汀鈣劑量增為10 mg/次,觀察2組在對(duì)照組基礎(chǔ)上將瑞舒伐他汀鈣劑量增為20 mg/次,療程均為8 w。采用彩色多普勒超聲儀觀察三組治療前后IMT變化情況,對(duì)比組間以及治療前后血脂、hs-CRP水平變化。結(jié)果治療前,三組患者h(yuǎn)s-CRP水平無統(tǒng)計(jì)學(xué)差別(P0.05),治療后hs-CRP水平均降低(P0.05),觀察2組hs-CRP水平降低程度最大(P0.05);治療前甘油三酯(TG)、總膽固醇(TC)、低密度脂蛋白膽固醇(LDL-C)、高密度脂蛋白膽固醇(HDL-C)水平無統(tǒng)計(jì)學(xué)差異(P0.05),治療后均顯著下降(P0.05),觀察2組降低程度最大(P0.05);治療前組間IMT值無統(tǒng)計(jì)學(xué)差異(P0.05),治療后,三組患者IMT值較治療前均下降(P0.05),觀察2組IMT值降低程度最大(P0.05)。三組治療后均無不良反應(yīng)。結(jié)論 CHD伴高脂血癥的老年患者服用瑞舒伐他汀鈣后,IMT增厚現(xiàn)象、血脂升高情況顯著改善,且療效與藥物劑量存在量效關(guān)系,同時(shí)發(fā)現(xiàn)hs-CRP與瑞舒伐他汀鈣存在密切關(guān)系,因此分析IMT的改善與患者機(jī)體內(nèi)hs-CRP間存在聯(lián)系。
[Abstract]:Objective to investigate the effects of different doses of rosuvastatin calcium on blood lipids, serum hypersensitive C-reactive protein hs-CRP and carotid intima-media thickness (IMT) in elderly patients with coronary heart disease (CHD) and hyperlipidemia. Methods from January 2011 to March 2015, 270 elderly patients who were admitted to hospital for CHD with hyperlipidemia were randomly divided into three groups: 90 patients in each group. All patients were treated with hypoglycemia, hypotension, nitrate ester and anticoagulant. In the control group, the dosage of rosuvastatin calcium was increased to 10 mg/ on the basis of the control group, and the dosage of rosuvastatin calcium was increased to 20 mg/ on the basis of the control group. The course of treatment was 8 weeks. Color Doppler ultrasound was used to observe the changes of IMT before and after treatment, and to compare the changes of serum lipids and hs-CRP between groups and before and after treatment. Results before treatment, There was no significant difference in hs-CRP levels among the three groups (P 0.05), but the levels of hs-CRP were all decreased after treatment. The hs-CRP levels in the two groups were observed to be the largest (P 0.05), and the levels of triglyceride, total cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) were observed before treatment. There was no significant difference in the level of HDL-C between the two groups (P 0.05), but all of them were significantly decreased after treatment (P 0.05). The maximum degree of reduction was observed in the two groups (P 0.05), and there was no significant difference in IMT between the two groups before and after treatment (P 0.05), and after treatment, there was no significant difference between the two groups (P 0.05). The IMT value of the three groups was lower than that of before treatment (P 0.05). The maximum decrease of IMT was observed in the two groups (P 0.05). There were no adverse reactions after treatment in all three groups. Conclusion CHD with hyperlipidemia in the elderly patients with rosuvastatin calcium, the phenomenon of hyperlipidemia, serum lipids increased significantly improved, and the efficacy and dose-effect relationship with the drug, and found that there is a close relationship between hs-CRP and rosuvastatin calcium. Therefore, the relationship between the improvement of IMT and hs-CRP in patients was analyzed.
【作者單位】： 江漢大學(xué)附屬醫(yī)院武漢市第六醫(yī)院心血管內(nèi)科;
【分類號(hào)】：R541.4;R589.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 劉兆奕;劉麗敏;;急性冠狀動(dòng)脈綜合征患者支架植入術(shù)后炎癥因子變化及瑞舒伐他汀的干預(yù)作用[J];臨床薈萃;2013年01期

2 陸志峰;;不同劑量瑞舒伐他汀鈣治療老年冠心病合并高脂血癥的療效對(duì)比分析[J];齊齊哈爾醫(yī)學(xué)院學(xué)報(bào);2013年04期

3 李煒;劉曉梅;張燕;;瑞舒伐他汀治療原發(fā)性高血壓合并高脂血癥的療效觀察[J];實(shí)用心腦肺血管病雜志;2013年05期

4 馬健浩;;瑞舒伐他汀對(duì)維持性血透心血管疾病發(fā)生率的影響[J];現(xiàn)代醫(yī)院;2013年05期

5 馬淑義;宋月平;;不同劑量瑞舒伐他汀對(duì)老年冠心病合并高脂血癥干預(yù)效果分析[J];中國預(yù)防醫(yī)學(xué)雜志;2013年07期

6 王志方;;瑞舒伐他汀對(duì)老年冠心病患者療效和安全性影響[J];中國煤炭工業(yè)醫(yī)學(xué)雜志;2010年09期

7 王麗娟;陳還珍;王芳;祁春雷;;國產(chǎn)瑞舒伐他汀對(duì)血脂及炎癥因子影響的臨床研究[J];當(dāng)代醫(yī)學(xué);2011年03期

8 李霞;王粵;李靜;;超聲觀察瑞舒伐他汀逆轉(zhuǎn)頸動(dòng)脈硬化斑塊的療效評(píng)價(jià)[J];中國醫(yī)藥指南;2011年23期

9 趙波;楊慶祥;趙云峰;劉琨;張健;;國產(chǎn)瑞舒伐他汀對(duì)冠心病患者血脂及炎癥因子的影響[J];實(shí)用臨床醫(yī)藥雜志;2011年23期

10 李沛;曾麗;;瑞舒伐他汀對(duì)原發(fā)性高血壓合并高脂血癥血脂和動(dòng)脈粥樣硬化的影響[J];四川醫(yī)學(xué);2011年12期

相關(guān)會(huì)議論文 前10條

1 賈紅兵;李肖惠;;瑞舒伐他汀對(duì)冠狀動(dòng)脈介入術(shù)后左室收縮功能和血漿炎癥相關(guān)因子的影響[A];全國第十三屆心臟學(xué)會(huì)、第十六屆心功能專業(yè)委員會(huì)和《心臟雜志》編委會(huì)聯(lián)合學(xué)術(shù)大會(huì)會(huì)議紀(jì)要[C];2013年

2 李廣平;付文良;徐曉娜;陸敏;;瑞舒伐他汀逆轉(zhuǎn)動(dòng)脈硬化斑塊以及與斑塊穩(wěn)定關(guān)系的實(shí)驗(yàn)研究[A];中華醫(yī)學(xué)會(huì)第11次心血管病學(xué)術(shù)會(huì)議論文摘要集[C];2009年

3 曹平良;李年娥;孫瑜婧;唐瓊珍;陳早芳;邱元芝;葛郁芝;;瑞舒伐他汀治療血脂異常的高危心血管病患者療效和安全性[A];江西省第六次中西醫(yī)結(jié)合心血管學(xué)術(shù)交流會(huì)論文集[C];2013年

4 陶貴周;唐偉敬;;瑞舒伐他汀對(duì)心肌梗死后細(xì)胞凋亡及心室重構(gòu)的影響[A];中華醫(yī)學(xué)會(huì)第11次心血管病學(xué)術(shù)會(huì)議論文摘要集[C];2009年

5 孫勇;郭航遠(yuǎn);劉龍斌;史亞非;孫愛靜;許富康;池菊芳;;瑞舒伐他汀抑制低密度脂蛋白受體基因缺陷小鼠基質(zhì)金屬蛋白酶-2表達(dá)和粥樣斑塊形成[A];中華醫(yī)學(xué)會(huì)第11次心血管病學(xué)術(shù)會(huì)議論文摘要集[C];2009年

6 杜瑞雪;葉平;;瑞舒伐他汀治療對(duì)周圍動(dòng)脈粥樣硬化患者粘附、趨化因子的影響[A];第十三次全國心血管病學(xué)術(shù)會(huì)議論文集[C];2011年

7 胡昕嬰;葛均波;孫愛軍;謝新星;;瑞舒伐他汀促大鼠急性心肌梗死后心肌組織修復(fù)的研究[A];第十三次全國心血管病學(xué)術(shù)會(huì)議論文集[C];2011年

8 仇集;;瑞舒伐他汀對(duì)急性ST段抬高型心肌梗死溶栓治療后血清炎癥因子和短期預(yù)后的影響[A];第三十屆航天醫(yī)學(xué)年會(huì)、第十三屆航天護(hù)理年會(huì)暨第四屆航天醫(yī)院管理論壇論文匯編[C];2014年

9 張繼雁;葛曉冬;徐平;;早期應(yīng)用瑞舒伐他汀鈣片對(duì)不穩(wěn)定性心絞痛冠狀動(dòng)脈血流儲(chǔ)備的影響[A];第十三次全國心血管病學(xué)術(shù)會(huì)議論文集[C];2011年

10 劉龍斌;史亞非;郭航遠(yuǎn);許富康;孫愛靜;池菊芳;;瑞舒伐他汀抑制LDL受體基因缺陷小鼠MMP-2表達(dá)和粥樣斑塊形成[A];2012年浙江省心電生理與起搏學(xué)術(shù)年會(huì)論文集[C];2012年

相關(guān)重要報(bào)紙文章 前4條

1 記者 徐述湘;瑞舒伐他汀可用于預(yù)防心血管病[N];中國醫(yī)藥報(bào);2008年

2 魏峗;瑞舒伐他汀可降低心血管事件[N];醫(yī)藥經(jīng)濟(jì)報(bào);2009年

3 亦舟;瑞舒伐他汀可以降低心血管事件的發(fā)生率[N];醫(yī)藥經(jīng)濟(jì)報(bào);2007年

4 記者　靖九江;拯救血管 降脂降壓是根本[N];中國醫(yī)藥報(bào);2006年

，

本文編號(hào)：1825502